CrystalsFirst achieves a major company milestone

structurally-enabling more than 40 drug targets for design of therapeutics.

CrystalsFirst’s MAGNET platform enables allosteric, covalent, non-covalent campaigns across a wide rage of ligand sizes from fragments, leads, drug candidates to peptides.

Our experience with targets encompasses:

Helicases
GTPases
Transcription factors
Kinases
E3 Ligases

and many others.